Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
Sponsor: Mayo Clinic
Summary
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. There is evidence that α-cell proglucagon processing is subject to paracrine regulation by the β-cell3. It is unclear if the effects of GLP1R agonism on islet GLP-1 differ in Type 1 diabetes (T1DM) compared to T2DM. This experiment will examine the effect of glycemic control ± a GLP1R agonist on islet GLP-1 in people with (T2DM) and without (T1DM) β-cells.
Official title: The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People
Key Details
Gender
All
Age Range
25 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-10-03
Completion Date
2029-03-31
Last Updated
2025-10-14
Healthy Volunteers
No
Conditions
Interventions
Liraglutide Pen Injector
Liraglutide 0.6mg
Saline Injections
Saline in syringes to serve as placebo for single blind study
Locations (1)
Mayo Clinic in Rochester
Rochester, Minnesota, United States